GlobeNewsWire
03 Aug 2026, 11:40 UTC · 2h ago
Helus Pharma Appoints Michael Halstead as Chief Executive Officer
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
GlobeNewsWire
03 Aug 2026, 11:40 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Helus Pharma expects topline data from its first pivotal Phase 3 study (APPROACH) for HLP003 in the treatment of Major Depressive Disorder in Q4 2026. — Topline Phase 3 results are the primary binary catalyst for clinical-stage biotech valuations.
+0.60Helus Pharma appointed Michael Halstead, former President of Intra-Cellular Therapies, as CEO. — Halstead has a proven track record of scaling a similar CNS company and overseeing a $14.6 billion exit to Johnson & Johnson.
+0.40Enrollment is complete for the APPROACH study, while enrollment continues for the second pivotal Phase 3 study, EMBRACE. — Completion of enrollment reduces execution risk and confirms the timeline for the Q4 data readout.
+0.20Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
Appointment of a highly experienced CEO with a track record of successful commercialization and M&A.
Mentioned only as the historical acquirer of Intra-Cellular Therapies.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
7h ago
